ArticleJournal of advanced veterinary and animal research2025
Mechanistic insights into
Article in Journal of advanced veterinary and animal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to make a comparative evaluation of the therapeutic efficacies of the Calotropis extract (CPE) and green silver nanoparticles (GSNPs) compared to praziquantel (PZQ) in treating mice infected with schistosomiasis, with a comprehensive assessment of host physio-logical responses. MATERIALS AND
methodsThe CpE-fabricated silver nanoparticles were characterized (UV-vis spectroscopy, transmission electron microscopy, and Fourier transform infrared). Five experimen-tal groups were conducted: uninfected, infected untreated, PZQ-, CpE-, and GSNP-treated. The parasitological, biochemical, histopathological, and ultrastructural approaches were employed in evaluating each treatment protocol.
resultsIt was found that the reduction of the worm burden and oogram count was significantly enhanced by both CpE and GSNPs, yet PZQ showed better antiparasitic effects. The antioxidant activity of GSNPs was more efficient, and they significantly restored hepatic (glutathione) as well as reduced (malondialdehyde) and (nitric oxide) levels. In addition, both CpE and GSNPs regulated apoptotic markers by inhibiting Bcl2-cell-associated X protein and enhancing B-cell lymphoma protein 2 expression, thereby inhibiting hepatocyte apoptosis. Histopathological examination revealed a reduction in granuloma size and hepatic fibrosis, along with an improved hepatoprotective potential of GSNPs. Biochemical analysis revealed increased activity of liver enzymes (alanine transaminase, aspartate transaminase, and gamma-glutamyl transferase) as well as markers of renal function (urea and creatinine), indicating they also had a systemic protective role. All treatments resulted in some ultrastructural alterations in worms.
conclusionThe normalized parasitological and physiological parameters were utilized in develop-ing a novel mathematical framework that facilitates more objective assessments for treatment pro-tocols. Although PZQ showed the highest efficacy against the parasite (total efficacy score: 71.8), the plant extract showed the highest efficacy in anti-fibrotic and anti-apoptotic properties (total efficacy score: 61.6). However, GSNPs showed balanced therapeutic benefits (total efficacy score: 51.1). This study indicated that comparison based on both the host physiological parameters and those of the parasite is more comprehensive for optimal anti-schistosomal treatment selection. This study also confirmed that treatments derived from plant sources may have complementary benefits over traditional chemotherapy through metabolic pathways involved in the host protective responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.